United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.

Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock

Pfizer stock has fallen 7.1% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat.

Pfizer Stock Is The Biggest Pharma — But Should You Buy It?

Merck

The four companies that now dominate global vaccine sales are Merck, Pfizer, Sanofi Pasteur and GlaxoSmithKline.

Top vaccine makers Merck and Pfizer target China and older adults next

Array BioPharma (ARRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Array BioPharma (ARRY) Rating Upgrade to Buy

Eli Lilly

Thursday market saw two very successful IPOs in the emerging biotech sector.

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

Pfizer Inc. (NYSE: PFE) said Wednesday that it reached a definitive agreement to acquire all the shares of Therachon Holding AG, a privately held clinical-stage biotech focused on rare diseases.

Pfizer Buys Rare Disease Biotech Therachon For $340M

Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.

Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates

It's been nearly seven years since the FDA refused to approve tafamidis's first new drug application, and the field is a lot more crowded now.

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Array BioPharma Inc. (ARRY) CEO Ron Squarer on Q3 2019 Results - Earnings Call Transcript

Array BioPharma (ARRY) delivered earnings and revenue surprises of 19.05% and 25.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Array BioPharma (ARRY) Reports Q3 Loss, Tops Revenue Estimates

Dow Jones component Pfizer gained approval Monday for a drug that treats a rare heart disease — potentially rivaling new drugs from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.

How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks

A few bumps in the road might be on the way, but this big pharma stock should have pretty smooth sailing over the next decade.

5 Reasons Why Pfizer Is a Great Stock to Buy and Hold for the Long Term

Pfizer recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecast for the full year 2019.

Pfizer Beats In Q1 But Lyrica Headwinds Will Likely Weigh On Near Term Growth

Pfizer reported better-then-expected earnings on April 30, but the stock is under a "death cross" and a negative weekly chart.

Pfizer Stock Rebounds Under Cloud of Negative Charts

Pfizer Inc. (PFE) CEO Albert Bourla on Q1 2019 Results - Earnings Call Transcript

The big drugmaker exceeded expectations in Q1 on both the top and bottom lines.

What You Need to Know About Pfizer's Q1 Earnings Beat

When Pfizer Inc. reported first-quarter 2019 results before markets opened Tuesday, the drugmaker posted adjusted diluted earnings per share (EPS) of $0.85 on revenues of $13.12 billion.

Why Pfizer Shareholders Are Smiling After Earnings

Pfizer (PFE) beat estimates for first-quarter earnings and sales and raised the mid-point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full-year sales.

Pfizer (PFE) Beats on Q1 Earnings & Sales, Raises EPS View

Shares of Pfizer rose 1.7% in premarket trade Tuesday after the company reported first-quarter earnings and revenue that beat expectations, while raising its full-year guidance.

Pfizer stock up 1.7% after earnings and revenue beat

Shares of Pfizer and Merck rose after reporting financial results that beat expectations.

Three major pharmaceutical companies just reported earnings — here’s how they did

Johnson & Johnson

Teladoc

UnitedHealth Group

There's a clear and present danger to many healthcare stocks that's more serious than anything ever before.

Why This Could Be the Most Dangerous Time Ever to Invest in Healthcare Stocks

AbbVie

Which big pharma stock is more likely to be the bigger winner over the long run?

AbbVie vs. Pfizer

Apple

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components. Short sellers are betting on these companies to fail, or at least for their share prices to fall handily.

Pfizer & Apple: The Most Shorted Dow Stocks in April

Merck announced FDA approval for Keytruda given in combination with Pfizer's Inlyta to treat front-line advanced kidney cancer patients.

Merck Maintains Status In Front-Line Cancer Space

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.

News for Pfizer Stock (PFE)